Recombinant interferon-gamma (rIFN-gamma) in dermatology

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Recombinant interferon-gamma (rIFN-gamma) has demonstrated therapeutic potential in various dermatological conditions.
• Understanding its function, pharmacokinetics, and application is crucial for optimizing treatment strategies.
• Previous reports suggest varying efficacy across different skin diseases.

Purpose of the Study:

• To review the function, pharmacokinetics, and therapeutic applications of rIFN-gamma in dermatology.
• To present clinical experiences with rIFN-gamma in a cohort of patients with diverse dermatological conditions.
• To evaluate the efficacy and safety of low-dose rIFN-gamma treatment.

Main Methods:

• A phase II study involving 57 patients with conditions including genital warts, psoriatic arthritis, psoriasis vulgaris, malignant melanoma, and others.
• Review of existing literature on rIFN-gamma's function, pharmacokinetics, and therapeutic use.
• Administration of low-dose rIFN-gamma (50-100 micrograms/day) and monitoring of patient outcomes and side effects.

Main Results:

• rIFN-gamma showed potential in treating genital warts, bowenoid papulosis, Behcet's disease, and microbial infections like leprosy and cutaneous leishmaniasis.
• No significant benefit was observed in patients with psoriatic arthritis or psoriasis vulgaris.
• Common side effects included mild fever (78%), fatigue (78%), and myalgia (65%).
• Increased serum triglyceride levels were noted, particularly in psoriatic patients.

Conclusions:

• rIFN-gamma may be indicated for specific dermatological conditions such as genital warts, bowenoid papulosis, Behcet's disease, and certain microbial infections.
• The study did not support the use of rIFN-gamma for psoriasis or psoriatic arthritis based on observed results.
• Low-dose rIFN-gamma is generally well-tolerated, but monitoring for side effects like fever, fatigue, myalgia, and elevated triglycerides is recommended.